AI Engines For more Details: Perplexity Kagi Labs You
Breast Cancer Treatment: Exemestane is indicated for the treatment of hormone receptor-positive early breast cancer in postmenopausal women who have already received tamoxifen treatment. It is also used in the treatment of advanced breast cancer after other hormonal treatments such as tamoxifen have failed.
Aromatase Inhibitor: Exemestane belongs to a class of drugs known as aromatase inhibitors. It works by irreversibly inhibiting the enzyme aromatase, which is responsible for converting androgens into estrogen. By blocking estrogen production, exemestane helps in reducing estrogen levels in the body, thereby slowing down or stopping the growth of hormone receptor-positive breast cancer cells.
Adjuvant Therapy: Exemestane may be used as adjuvant therapy following surgery or radiation therapy in postmenopausal women with hormone receptor-positive early breast cancer to reduce the risk of cancer recurrence.
Estrogen Suppression: Exemestane effectively reduces estrogen levels in the body, which may lead to menopausal-like symptoms such as hot flashes, sweating, vaginal dryness, and mood changes. These symptoms are usually temporary and may improve over time.
Bone Health: Estrogen plays a crucial role in maintaining bone density, and reducing estrogen levels with exemestane may lead to bone loss and an increased risk of osteoporosis. Bone density monitoring and supplementation with calcium and vitamin D may be recommended to mitigate this risk.
Cardiovascular Effects: Estrogen has protective effects on the cardiovascular system, and reducing estrogen levels with exemestane may increase the risk of cardiovascular events such as heart disease and stroke. Monitoring of cardiovascular health and appropriate interventions may be necessary in patients receiving exemestane.
Liver Function: Exemestane is metabolized in the liver, so monitoring of liver function tests may be necessary during treatment to detect any signs of liver toxicity.
Interactions: Exemestane may interact with other medications, including hormonal therapies and certain medications that are metabolized by the liver. It's essential to inform your healthcare provider about all medications you are taking before starting exemestane.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Bifidobacterium adolescentis | species | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.7 | 0.7 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4.6 | 0.3 | 14.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.2 | 2.4 | -0.09 |
| Allergies | 5.2 | 2.9 | 0.79 |
| Allergy to milk products | 1.4 | 1 | 0.4 |
| Alopecia (Hair Loss) | 1.3 | 1.3 | |
| Alzheimer's disease | 4.4 | 5.3 | -0.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.2 | 0.6 | 2.67 |
| Ankylosing spondylitis | 3 | 0.9 | 2.33 |
| Anorexia Nervosa | 1.6 | 2.6 | -0.63 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.3 | 1.33 |
| Asthma | 4.5 | 2.8 | 0.61 |
| Atherosclerosis | 1.2 | 1.5 | -0.25 |
| Atrial fibrillation | 3.2 | 1.4 | 1.29 |
| Autism | 6.9 | 7.2 | -0.04 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.8 | 0.8 | |
| Bipolar Disorder | 1.8 | 1.4 | 0.29 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Cancer (General) | 0.6 | 2.6 | -3.33 |
| Carcinoma | 3.5 | 2.6 | 0.35 |
| Celiac Disease | 1.2 | 4 | -2.33 |
| Cerebral Palsy | 1.5 | 1.3 | 0.15 |
| Chronic Fatigue Syndrome | 4.5 | 4.8 | -0.07 |
| Chronic Kidney Disease | 3.6 | 1.9 | 0.89 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.9 | 1.4 | -0.56 |
| Chronic Urticaria (Hives) | 0.8 | 0.4 | 1 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.3 | -0.86 |
| Cognitive Function | 2.5 | 1.6 | 0.56 |
| Colorectal Cancer | 4.5 | 2.2 | 1.05 |
| Constipation | 1 | 0.7 | 0.43 |
| Coronary artery disease | 1.2 | 1.6 | -0.33 |
| COVID-19 | 8.4 | 9.6 | -0.14 |
| Crohn's Disease | 5.3 | 4.5 | 0.18 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 1.9 | -1.9 | |
| deep vein thrombosis | 0.2 | 1.4 | -6 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 9.2 | 7.2 | 0.28 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 0.8 | 1.5 | -0.88 |
| Endometriosis | 2 | 1.7 | 0.18 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 1.7 | 1.6 | 0.06 |
| erectile dysfunction | 0.5 | 0.3 | 0.67 |
| Fibromyalgia | 2.6 | 1.1 | 1.36 |
| Functional constipation / chronic idiopathic constipation | 3.8 | 3.1 | 0.23 |
| gallstone disease (gsd) | 1.9 | 1 | 0.9 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 1.2 | -2 |
| Generalized anxiety disorder | 1.2 | 1.9 | -0.58 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 0.4 | 4.25 |
| Graves' disease | 1.9 | 3 | -0.58 |
| Gulf War Syndrome | 0.6 | 1.1 | -0.83 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 2.9 | 1.6 | 0.81 |
| Heart Failure | 2.7 | 1.4 | 0.93 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 1 | 0.6 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.3 | 0.67 |
| hyperglycemia | 1.2 | 1.6 | -0.33 |
| Hyperlipidemia (High Blood Fats) | 1 | 0.3 | 2.33 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.6 | 5.6 | -0.56 |
| Hypothyroidism | 0.2 | 0.7 | -2.5 |
| Hypoxia | 2.2 | 0.3 | 6.33 |
| IgA nephropathy (IgAN) | 1.6 | 3.8 | -1.37 |
| Inflammatory Bowel Disease | 5.5 | 7.8 | -0.42 |
| Insomnia | 1.6 | 2.9 | -0.81 |
| Intelligence | 0.7 | 0.1 | 6 |
| Intracranial aneurysms | 1.2 | 0.3 | 3 |
| Irritable Bowel Syndrome | 5.8 | 4.6 | 0.26 |
| ischemic stroke | 2.7 | 1.1 | 1.45 |
| Liver Cirrhosis | 5.9 | 4.1 | 0.44 |
| Long COVID | 5 | 8.3 | -0.66 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.9 | 1.3 | -0.44 |
| Mast Cell Issues / mastitis | 0.3 | 0.6 | -1 |
| ME/CFS with IBS | 0.9 | 1.8 | -1 |
| ME/CFS without IBS | 1.4 | 2.1 | -0.5 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.3 | 0.7 | 2.29 |
| Metabolic Syndrome | 6.1 | 7.1 | -0.16 |
| Mood Disorders | 9.6 | 5.7 | 0.68 |
| multiple chemical sensitivity [MCS] | 0.8 | 0.1 | 7 |
| Multiple Sclerosis | 5.7 | 4.3 | 0.33 |
| Multiple system atrophy (MSA) | 1.4 | 0.7 | 1 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 3.3 | -10 |
| Neuropathy (all types) | 0.9 | 1.6 | -0.78 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.1 | 4.6 | -0.12 |
| NonCeliac Gluten Sensitivity | 1.6 | 0.6 | 1.67 |
| Obesity | 9 | 6.5 | 0.38 |
| obsessive-compulsive disorder | 4.3 | 2.8 | 0.54 |
| Osteoarthritis | 1.3 | 1.3 | 0 |
| Osteoporosis | 1.9 | 1.6 | 0.19 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 7 | 3.9 | 0.79 |
| Polycystic ovary syndrome | 4.1 | 3.4 | 0.21 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1 | 0.2 |
| Primary sclerosing cholangitis | 2.4 | 2 | 0.2 |
| Psoriasis | 2.9 | 2 | 0.45 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.7 | 2.9 | 1.31 |
| Rosacea | 0.9 | 0.7 | 0.29 |
| Schizophrenia | 6.4 | 2.9 | 1.21 |
| scoliosis | 1.2 | -1.2 | |
| Sjögren syndrome | 2.1 | 2.9 | -0.38 |
| Sleep Apnea | 1.6 | 1.6 | 0 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 0.7 | 0.57 |
| Stress / posttraumatic stress disorder | 2.5 | 2.7 | -0.08 |
| Systemic Lupus Erythematosus | 2.5 | 2 | 0.25 |
| Tic Disorder | 1 | 1.2 | -0.2 |
| Tourette syndrome | 1 | 0.3 | 2.33 |
| Type 1 Diabetes | 2.8 | 4 | -0.43 |
| Type 2 Diabetes | 6.4 | 5.6 | 0.14 |
| Ulcerative colitis | 3.3 | 5.7 | -0.73 |
| Unhealthy Ageing | 3.4 | 1.7 | 1 |
| Vitiligo | 1.9 | 1.1 | 0.73 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
